Maravai LifeSciences Holdings, Inc. (MRVI)
NASDAQ: MRVI · Real-Time Price · USD
2.400
+0.230 (10.60%)
May 20, 2025, 4:00 PM - Market closed
MRVI Stock Forecast
Stock Price Forecast
According to 8 professional analysts, the 12-month price target for MRVI stock ranges from a low of $2.00 to a high of $13. The average analyst price target of $6.84 forecasts a 185.00% increase in the stock price over the next year.
Price Target: $6.84 (+185.00%)
Analyst Consensus: Hold
Analyst Ratings
The average analyst rating for MRVI stock is "Hold". This means that analysts believe this stock is likely to perform similarly to the overall market.
Recommendation Trends
| Rating | Dec '24 | Jan '25 | Feb '25 | Mar '25 | Apr '25 | May '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 3 | 3 | 1 | 2 | 2 | 2 |
| Buy | 3 | 3 | 2 | 2 | 2 | 2 |
| Hold | 4 | 4 | 5 | 5 | 5 | 5 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 1 | 1 | 1 | 1 | 1 | 1 |
| Total | 11 | 11 | 9 | 10 | 10 | 10 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Craig-Hallum | Craig-Hallum | Strong Buy Maintains $12 → $10 | Strong Buy | Maintains | $12 → $10 | +316.67% | May 13, 2025 |
| Baird | Baird | Hold Maintains $3 → $2 | Hold | Maintains | $3 → $2 | -16.67% | May 13, 2025 |
| Morgan Stanley | Morgan Stanley | Hold Maintains $7 → $5 | Hold | Maintains | $7 → $5 | +108.33% | Mar 25, 2025 |
| UBS | UBS | Hold Maintains $8 → $2.5 | Hold | Maintains | $8 → $2.5 | +4.17% | Mar 21, 2025 |
| B of A Securities | B of A Securities | Strong Buy Maintains $9 → $8 | Strong Buy | Maintains | $9 → $8 | +233.33% | Mar 3, 2025 |
Financial Forecast
Revenue This Year
197.86M
from 259.19M
Decreased by -23.66%
Revenue Next Year
220.17M
from 197.86M
Increased by 11.28%
EPS This Year
-0.28
from -1.05
EPS Next Year
-0.22
from -0.28
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 215.3M | 245.7M | 304.9M | ||
| Avg | 197.9M | 220.2M | 246.5M | ||
| Low | 181.3M | 197.0M | 210.7M |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | -17.0% | 24.2% | 38.5% | ||
| Avg | -23.7% | 11.3% | 12.0% | ||
| Low | -30.0% | -0.4% | -4.3% |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | -0.18 | -0.07 | -0.04 | ||
| Avg | -0.28 | -0.22 | -0.18 | ||
| Low | -0.41 | -0.40 | -0.39 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | - | - | - | ||
| Avg | - | - | - | ||
| Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.